Michael E Ballard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3665343/publications.pdf

Version: 2024-02-01

623734 713466 20 890 14 21 citations g-index h-index papers 21 21 21 1209 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Low Striatal Dopamine D2-type Receptor Availability is Linked to Simulated Drug Choice in Methamphetamine Users. Neuropsychopharmacology, 2018, 43, 751-760.	5.4	17
2	Effects of Acute Methamphetamine on Emotional Memory Formation in Humans: Encoding vs Consolidation. PLoS ONE, 2015, 10, e0117062.	2.5	11
3	Low Dopamine D2/D3 Receptor Availability is Associated with Steep Discounting of Delayed Rewards in Methamphetamine Dependence. International Journal of Neuropsychopharmacology, 2015, 18, pyu119-pyu119.	2.1	56
4	Chronic methamphetamine abuse and corticostriatal deficits revealed by neuroimaging. Brain Research, 2015, 1628, 174-185.	2.2	147
5	Striatal Dopamine D2/D3 Receptor Availability Is Associated with Executive Function in Healthy Controls but Not Methamphetamine Users. PLoS ONE, 2015, 10, e0143510.	2.5	10
6	Amphetamine Increases Errors During Episodic Memory Retrieval. Journal of Clinical Psychopharmacology, 2014, 34, 85-92.	1.4	30
7	Pre-encoding administration of amphetamine or THC preferentially modulates emotional memory in humans. Psychopharmacology, 2013, 226, 515-529.	3.1	23
8	Effects of delta-9-tetrahydrocannabinol on evaluation of emotional images. Journal of Psychopharmacology, 2012, 26, 1289-1298.	4.0	42
9	Psychoactive drugs and false memory: comparison of dextroamphetamine and delta-9-tetrahydrocannabinol on false recognition. Psychopharmacology, 2012, 219, 15-24.	3.1	31
10	Behavioral characterization of a mutant mouse strain lacking d-amino acid oxidase activity. Behavioural Brain Research, 2011, 217, 81-87.	2.2	20
11	Combined effects of acute, very-low-dose ethanol and delta(9)-tetrahydrocannabinol in healthy human volunteers. Pharmacology Biochemistry and Behavior, 2011, 97, 627-631.	2.9	42
12	The use of the scopolamine-induced cognitive impairment model to translate on-target activity for ABT-894 from rodents/monkeys to humans: Preclinical evidences. Biochemical Pharmacology, 2011, 82, 1043.	4.4	1
13	Acute delta- and kappa-opioid agonist pretreatment potentiates opioid antagonist-induced suppression of water consumption. Brain Research Bulletin, 2008, 76, 597-604.	3.0	3
14	Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine. Behavioural Brain Research, 2007, 182, 1-11.	2.2	25
15	The drug-induced helplessness test: an animal assay for assessing behavioral despair in response to neuroleptic treatment. Psychopharmacology, 2007, 190, 1-11.	3.1	14
16	Effect of Dopamine D3 Antagonists on PPI in DBA/2J Mice or PPI Deficit Induced by Neonatal Ventral Hippocampal Lesions in Rats. Neuropsychopharmacology, 2006, 31, 1382-1392.	5.4	24
17	Lack of cataleptogenic potentiation with non-imidazole H3 receptor antagonists reveals potential drug–drug interactions between imidazole-based H3 receptor antagonists and antipsychotic drugs. Brain Research, 2005, 1045, 142-149.	2.2	52
18	2. Histaminergic mechanisms in the CNS. Inflammation Research, 2005, 54, S23-S24.	4.0	14

#	Article	IF	CITATIONS
19	Pharmacological Properties of ABT-239 [4-(2-{2-[(2 <i>R</i>)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H ₃ Receptor Antagonist. Journal of Pharmacology and Experimental	2.5	253
20	Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology, 2004, 176, 312-319.	3.1	74